50% OFF SITEWIDE · Orders before 4PM PST ship same day
50% OFF SITEWIDEOrders before 4PM PST ship same day
Science

Single, Dual, and Triple Receptor Agonists: GLP Class Research Peptides Explained

Gloved hand holding a microcentrifuge tube with a sample in the laboratory

Few areas of peptide science have moved as quickly as incretin research. In roughly a decade, the field has progressed from single-receptor GLP-1 agonists to dual and now triple receptor compounds, each generation adding a new signaling dimension for metabolic research. This guide maps the three classes, explains what each added and why, and lays out how to choose compounds and design comparisons across them. For the underlying physiology, start with A Researcher’s Overview of GLP Receptor Agonists.

Why Generations

The progression was not planned; it followed the evidence. Each generation began as a research question about whether an additional receptor would add signal on top of the previous one, and each time the answer in preclinical models was yes. The result is a set of compounds that differ by exactly one receptor at each step, which is unusually convenient for research: the generations are their own controls.

Generation One: GLP-1 Receptor Agonists

The foundation of the field is the GLP-1 receptor agonist: compounds modeled on the incretin hormone GLP-1, engineered for extended stability through DPP-4-resistant substitutions and, in the long-acting molecules, a fatty-acid side chain that binds albumin. Activation of the GLP-1 receptor produces glucose-dependent insulin release, glucagon suppression, slower gastric emptying, and reduced feeding-pathway via brainstem and hypothalamic circuits.

In research settings, GLP1-S (see our GLP-1 agonist overview) serves as the reference compound. Laboratories use it to study GLP-1 receptor activation, trafficking and desensitization, hypothalamic signaling, and glucose homeostasis, and as the baseline against which newer multi-agonists are compared. A single agonist is also the right tool whenever the question is specifically about the GLP-1 receptor, because it introduces no other variable.

Generation Two: Dual GIP/GLP-1 Agonists

The second generation adds glucose-dependent insulinotropic polypeptide (GIP) signaling to the same molecule. GIP is the other incretin hormone, released from the upper intestine, acting on beta cells and on endocrine tissue. The leading dual agonist is built on a GIP backbone with substitutions that add GLP-1 receptor activity, and it is deliberately GIP-weighted.

GLP2-T (see our dual-agonist overview) activates both receptors, letting researchers examine how paired incretin signaling differs from single-receptor activation, a question with substantial published literature on glycemic response and metabolic endpoints in preclinical models. The class also opened the “GIP paradox”: both activating and blocking GIPR appear to improve metabolic outcomes in rodents, and resolving that is an active research front.

Generation Three: Triple Agonists

The frontier is triple agonism: GLP-1, GIP, and glucagon receptors engaged by one molecule. The glucagon component adds an energy-expenditure and hepatic fat-oxidation dimension that laboratories study alongside the incretin and insulin pathways of the first two generations, with the GLP-1 arm offsetting glucagon’s glucose-raising effect. GLP3-R (see our triple-agonist overview) represents this class in research catalogs. Designing a tri-agonist is harder than a dual, because the three receptors prefer partly conflicting sequences, and the balance among them is the central design variable.

The Three Generations Side by Side

Generation 1 Generation 2 Generation 3
Receptors GLP-1R GLP-1R + GIPR GLP-1R + GIPR + GCGR
Backbone GLP-1 (or exendin-4) GIP GIP
Added mechanism Incretin effect, gastric signaling, gastric emptying Second incretin axis, endocrine effects Energy expenditure, hepatic fat oxidation
Key design challenge DPP-4 resistance, half-life Receptor balance (GIP-weighted) Three-way balance; keeping glucagon arm in check
Research compound GLP1-S GLP2-T GLP3-R
Approximate mass ~4,114 Da ~4,813 Da ~4,731 Da

Beyond the GLP Family: Amylin Analogs

A parallel research track examines amylin receptor agonism. Amylin is co-secreted with insulin and acts on calcitonin-receptor-based receptors in the brainstem to slow gastric emptying and signal gastric signaling through a pathway distinct from GLP-1’s. Cagrilintide is the leading research compound here, frequently studied in combination designs with GLP-1 class peptides to model the dual-hormone approaches found in current metabolic literature. See Cagrilintide and the Amylin Pathway.

Designing a Cross-Generation Comparison

The generations invite side-by-side studies, but three design decisions determine whether the comparison means anything.

Dose matching. The three compounds have different potencies at the GLP-1 receptor they share. Matching by mass, by GLP-1R activity (from a cAMP assay), or by a functional endpoint such as feeding-pathway each produces a different experiment. State which you chose and why.

Isolating the added receptor. The cleanest way to attribute an effect to GIPR or GCGR is to block it: a dual agonist plus a GIPR antagonist should behave like a single agonist, and a triple agonist plus a glucagon receptor antagonist like a dual. Knockout cell lines serve the same purpose in vitro.

Species. Rodent and human GIP and glucagon biology differ in known ways; results in mice do not automatically transfer, and the literature’s translational gaps are themselves worth studying.

Handling Across the Class

All three generations are long, acylated peptides with the same handling needs: gentle reconstitution in bacteriostatic water, no shaking, low-binding tubes, refrigeration, and protection from light. Purity matters more for these than for short peptides, because deletion impurities in a 39-residue sequence can have receptor activity of their own; see Understanding Peptide Purity.

Choosing Compounds for Metabolic Research

Comparative incretin studies depend on consistent, verified material across arms. Our Metabolic Research collection covers all three generations plus the amylin pathway, each batch third-party tested to 99%+ purity with a Certificate of Analysis. Where the field is heading next is covered in The Multi-Agonist Era.

All products discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.

Research use only. The compounds discussed on this blog are intended for in-vitro laboratory research. Nothing here is medical advice, and none of these materials are for human or veterinary use.

Research Materials

Compounds referenced in this article, each lot third-party tested with a Certificate of Analysis.

GLP1-S Incretin & Metabolic Research GLP1-S View product → GLP2-T Incretin & Metabolic Research GLP2-T View product → GLP3-R Incretin & Metabolic Research GLP3-R View product → Cagrilintide Incretin & Metabolic Research Cagrilintide View product →

Compound data: Cagrilintide data sheet All data sheets →

Keep Reading

Molecular structure comparison of tesamorelin and sermorelin for laboratory research.
November 18, 2026

Tesamorelin vs. Sermorelin: Research Differences

Read →
In vitro receptor signaling research comparing ipamorelin and GHRP-6 pathways.
November 16, 2026

Ipamorelin vs. GHRP-6: Research Differences

Read →
Best Third
November 12, 2026

Best Third-Party Tested Peptides for Research Labs

Read →

← All Articles